| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $94M | ||
| $82M |
Buys | $49,999,983 | 1 | 6 |
Sells | $5,825,050 | 17 | 94 |
| Liu Brian Guan-Chyun | director | 1 | $50M | 0 | $0 | $50M |
| POST LEONARD E | director | 0 | $0 | 11 | $549,260 | $-549,260 |
| Mulay James | director | 0 | $0 | 5 | $2.5M | $-2.5M |
| Song Hong Fang | director | 0 | $0 | 1 | $2.78M | $-2.78M |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Over the last 12 months, insiders at CG Oncology, Inc. Common stock have bought $50M and sold $5.83M worth of CG Oncology, Inc. Common stock stock.
On average, over the past 5 years, insiders at CG Oncology, Inc. Common stock have bought $28.8M and sold $12.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Liu Brian Guan-Chyun (director) — $50M.
The last purchase of 1,515,151 shares for transaction amount of $50M was made by Liu Brian Guan-Chyun (director) on 2025‑09‑11.
| 2025-11-17 | Sale | POST LEONARD E | director | 1,000 0.0013% | $41.43 | $41,430 | +1.03% | |
| 2025-10-13 | Sale | POST LEONARD E | director | 1,000 0.0013% | $43.25 | $43,250 | -2.84% | |
| 2025-10-09 | Sale | Mulay James | director | 5,903 0.0077% | $43.99 | $259,673 | -6.01% | |
| 2025-09-30 | Sale | POST LEONARD E | director | 5,000 0.0065% | $40.09 | $200,450 | +3.46% | |
| 2025-09-29 | Sale | Mulay James | director | 12,755 0.0168% | $39.19 | $499,868 | +6.47% | |
| 2025-09-19 | Sale | Mulay James | director | 3,574 0.005% | $38.99 | $139,350 | +12.11% | |
| 2025-09-18 | Sale | Mulay James | director | 19,112 0.0252% | $39.01 | $745,559 | +6.41% | |
| 2025-09-15 | Sale | POST LEONARD E | director | 1,000 0.0013% | $35.10 | $35,100 | +18.53% | |
| 2025-09-11 | Liu Brian Guan-Chyun | director | 1.52M 1.9766% | $33.00 | $50M | +23.46% | ||
| 2025-09-05 | Sale | Mulay James | director | 27,015 0.0338% | $31.53 | $851,797 | +23.10% | |
| 2025-09-03 | Sale | Song Hong Fang | director | 100,000 0.1272% | $27.80 | $2.78M | +40.81% | |
| 2025-09-03 | Sale | POST LEONARD E | director | 1,000 0.0013% | $28.00 | $28,000 | +40.81% | |
| 2025-07-17 | Sale | POST LEONARD E | director | 2,000 0.0028% | $28.00 | $56,000 | +37.90% | |
| 2025-05-21 | Sale | POST LEONARD E | director | 1,000 0.0014% | $28.00 | $28,000 | +37.76% | |
| 2025-04-28 | Sale | POST LEONARD E | director | 1,000 0.0018% | $30.76 | $30,760 | +10.62% | |
| 2025-03-17 | Sale | POST LEONARD E | director | 1,000 0.0013% | $28.00 | $28,000 | -2.13% | |
| 2025-02-18 | Sale | POST LEONARD E | director | 1,000 0.0013% | $28.61 | $28,610 | -1.39% | |
| 2025-01-13 | Sale | POST LEONARD E | director | 1,000 0.0014% | $29.66 | $29,660 | -3.97% | |
| 2024-12-16 | Sale | Song Hong Fang | director | 700,000 1.0073% | $28.00 | $19.6M | -5.49% | |
| 2024-12-16 | Sale | POST LEONARD E | director | 1,000 0.0015% | $28.84 | $28,840 | -5.49% |
| Song Hong Fang | director | 2903931 3.8737% | $157.39M | 0 | 2 | |
| Liu Brian Guan-Chyun | director | 1515151 2.0211% | $82.12M | 1 | 0 | |
| POST LEONARD E | director | 0 0% | $0 | 0 | 13 | |
| Mulay James | director | 0 0% | $0 | 0 | 5 | |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 10 percent owner | 400000 0.5336% | $21.68M | 1 | 0 | <0.0001% |
$159,914,414 | 243 | 18.52% | $3.94B | |
$66,736,176 | 136 | 27.54% | $4.07B | |
$193,151,375 | 134 | 8.18% | $4.41B | |
$52,263,649 | 70 | 1.18% | $4.27B | |
$224,382,625 | 44 | 27.62% | $4.27B | |
$140,165,669 | 33 | 85.24% | $4.56B | |
$1,275,975,557 | 32 | 19.44% | $4.53B | |
$137,061,250 | 16 | 23.01% | $3.46B | |
$174,105,409 | 15 | 10.88% | $3.45B | |
$1,248,715 | 10 | 5.66% | $3.32B | |
$1,711,150 | 9 | 31.59% | $3.62B | |
$25,064,843 | 9 | 12.75% | $4.3B | |
$45,445,266 | 9 | -24.96% | $3.28B | |
$32,575,266 | 8 | 37.03% | $3.26B | |
$2,246,813 | 6 | 70.15% | $4.52B | |
$182,500,000 | 6 | 29.00% | $3.67B | |
$461,215 | 5 | 10.35% | $3.89B | |
$50,990,767 | 2 | 19.79% | $4.28B | |
CG Oncology, Inc. Common stock (CGON) | $7,600,000 | 1 | -4.05% | $4.06B |
| Increased Positions | 89 | +47.59% | 9M | +11.18% |
| Decreased Positions | 79 | -42.25% | 7M | -9.13% |
| New Positions | 34 | New | 1M | New |
| Sold Out Positions | 21 | Sold Out | 2M | Sold Out |
| Total Postitions | 197 | +5.35% | 78M | +2.05% |
| Vanguard Group Inc | $274,865.00 | 8.12% | 6.58M | +670,770 | +11.36% | 2025-09-30 |
| Decheng Capital Llc | $266,272.00 | 7.87% | 6.37M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $230,379.00 | 6.81% | 5.51M | +4M | +190.31% | 2025-09-30 |
| Blackrock, Inc. | $191,670.00 | 5.66% | 4.59M | +130,091 | +2.92% | 2025-09-30 |
| Fmr Llc | $161,552.00 | 4.77% | 3.87M | +9,541 | +0.25% | 2025-09-30 |
| Tcg Crossover Management, Llc | $153,378.00 | 4.53% | 3.67M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $137,210.00 | 4.05% | 3.28M | 0 | 0% | 2025-09-30 |
| Foresite Capital Management Vi Llc | $92,835.00 | 2.74% | 2.22M | 0 | 0% | 2025-09-30 |
| Alliancebernstein L.P. | $89,352.00 | 2.64% | 2.14M | -26,095 | -1.21% | 2025-09-30 |
| Ubs Group Ag | $88,857.00 | 2.63% | 2.13M | -102,975 | -4.62% | 2025-09-30 |